GUANINE INC.
Guanine eOligo Biosensor


Our electric oligonucleotide (eOligo) biosensor
helps professionals diagnose and treat
complex diseases more quickly
and at a fraction of the cost




Guanine’s eOligo biosensor quantifies low concentration nucleic acids, proteins, small molecules, cells and redox materials in a single assay using an inexpensive test cartridge and mobile device

ADVANCED BLOOD TESTS: “ Ultrasensitive detection of circulating tumor DNA or other low-abundance biomarkers in blood could transform cancer diagnostics, but the challenge is to develop cost-effective platforms that maintain high sensitivity without requiring expensive infrastructure." — Dr. Daniel A. Haber, Director, Massachusetts General Hospital Cancer Center. Commenting on liquid biopsy advancements.

PRECISION HEALTH AI “ The bottleneck for AI in precision health isn’t the algorithms—it’s the lack of affordable, multiplexed diagnostics that can detect low-concentration molecules like RNAs, proteins, and metabolites in a single assay. Until we solve this, precision medicine will remain a niche.”  - Eric Topol, Director of the Scripps Research Translational Institute. The Lancet Digital Health Opinion Piece.

Picture


Guanine’s affordable multiplex
multi-analyte platform enables a new generation of advanced blood tests and precision health AI

Advanced blood tested augmented by precision health AI can greatly improve outcomes in cancer, neurodegenerative diseases, cardiac disease and chronic diseases.

Guanine's eOligo biosensor can affordably provide large quantities of
low concentration biomarkers to enable precision test results and AI datasets.

Picture
Picture

Our upcoming developer kit will enable assay developers to create advanced cost blood that can be migrated to mobile test cartridges

Picture
Guanine was incubated at Mount Sinai's Elementa Labs.

Mount Sinai specialists told us that ED physicians only have 1 hour to decide which antibiotics to provide to elderly and immunocompromised sepsis patients. The ideal test should:
  • Recommend appropriate antibiotics and MIC value in 1 hour of sample collection
  • Detect dozens of pathogens and resistance genes
  • Conduct the test in the ER without a technician
  • Transmit the results to EMR/EHR
  • Employ a low cost per sample and mobile instrument
  • Provide quantitative results for AI algorithms and future precision medicine


Sepsis is the greatest cause of
hospital deaths and non-reimbursed costs


Our eOligo biosensor can reduce the time
for correct sepsis antibiotics from 3 days to 1 hour


Picture
Our upcoming sepsis infection will allow ER physicians
to get antibiotic type and MIC value in 1 hour


Picture

Our quantitative test provides more information for better decision-making
for infections as well as industrial pathogens and biodefense


Picture

Our eOligo biosensor inexpensively quantifies multiple low-level nucleic acids, proteins, small molecules, cells and redox targets in a single blood sample as input to AI/ML algorithms.

Real-time blood constituent quantities will enhance other information and provide a new generation of precision health interventions.

Picture

Guanine stands apart from other electrochemical biosensors
by attaching targets with millions of electric oligonucleotide (eOligo)
guanine molecules per target instead of only 1 tag to detect low concentrations


Picture
Our electric oligonucleotide (eOligo) enables
multi-analyte quantification, multiplexing, ultra-low
limit of detection and high sensitivity and specificity


Picture


DNA Methylation


Our eOligo biosensor can be used to quantify specific genes and associated 5mC and 5hmC without bisulfate conversion, PCR or sequencing
Picture
Our predecessor company was spun out from NASA Ames.

We commercialized NASA's carbon nanotube sensor with an automated instrument that
filter concentrated 10L of potable water and then captured target pathogens with magnetic separation
in advance of detecting guanine molecules in lysed pathogen RNA.

Picture

Our third generation platform saves valuable time by attaching targets with millions of eOligos instead of replicating millions of copies with culture or PCR

Get to know our technology

PATENT
Bioanalyte Signal Amplification and Detection with Artificial Intelligence Diagnosis.
US 11,105,801
Picture
PATENT
Ultra-Sensitive Bioanalyte Quantification from Self-Assembled Quadruplex Tags.
US 11,175,285
Picture

PUBLICATION
Detection of Pathogens and Antimicrobial Resistance Genes at Low Concentration via Electrochemical Oligonucleotide Tags 
Gordon, N., Bawa, R., Palmateer, G.
Eng. Proc. (2023), 35, 28. https://doi.org/10.3390/IECB2023-14584

Picture
PUBLICATION
Carbapenem-Resistant Enterobacteriaceae Testing in 45 Minutes using Oligonucleotide Detection Tags
Gordon, N., Bawa, R., Palmateer, G., Rajabi, M., Gordon J.B., Kotb, N.M., Balasubramaniyam, R, Gordon, B.R. Advances in Medical Imaging, Detection, and Diagnosis. Volume 4, Chapter 26, Jenny Stanford Publishing (2023)
Picture
Our pedigree evolved from nanotech pioneers, pathogen testing, spearheading a NASA biosensor spinoff and incubating in Mount Sinai's Elementa Labs
Picture
Neil Gordon
B.Eng, MBA

President & CEO
email  LinkedIn

Picture
Raj Bawa
MD, PhD
VP and
Chief IP Officer

Picture
Garry Palmateer M.Sc.
Vice President

Send us a message

Guanine Inc.

Mail
7 University Place, Suite B210
Rensselaer, NY 12144-3463

Telephone
(514) 813-7936

email
[email protected]

Submit
Picture



Copyright 2025 © Guanine Inc.
All rights reserved.